TABLE 4.
Summary of primary and key secondary efficacy endpoints by baseline MIC cutoff values for ceftolozane/tazobactama
| MIC, μg/mL | 28-day all-cause mortality, n/N (%) | Clinical cure at TOC, n/N (%) |
|---|---|---|
| ≤1 | 19/142 (13.4) | 102/142 (71.8) |
| >1 to ≤2 | 3/19 (15.8) | 11/19 (57.9) |
| >2 to ≤4 | 1/16 (6.3) | 12/16 (75.0) |
| >4 to ≤8 | 2/11 (18.2) | 3/11 (27.3) |
| >8 to ≤256 | 11/43 (25.6) | 23/43 (53.5) |
a
TOC, test of cure. Due to the small number of isolates at MIC cutoff values of >8 to ≤256 μg/mL, participants within this range were combined for analysis. The MIC value used in this analysis corresponded to the highest MIC for relevant pathogens identified at baseline for each participant.